Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Plos One|October 21, 2024
Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysisDenise Evans, Kamban Hirasen, Clive Ramushu, et al.
Clinical Pharmacology and Therapeutics|June 18, 2026
Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen (BPaMZ) for Pulmonary Drug-Resistant TuberculosisPauline Howell, Antonio Lombardi, William Brumskine, et al.
AIDS (London, England)|February 5, 2011
First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trialAndrea L Ciaranello, Shahin Lockman, Kenneth A Freedberg, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|February 10, 2026
Treatment Outcomes and Drug-Related Adverse Events Across Four Short-Course RR-TB Regimens in South Africa: A Retrospective AnalysisNorbert Ndjeka, Rubeshan Perumal, Kamila Romanowski, et al.
BMJ Open|December 4, 2021
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the PhilippinesGabriela Beatriz Gomez, Mariana Siapka, Francesca Conradie, et al.
The Lancet. Infectious Diseases|May 5, 2022
Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort studyNorbert Ndjeka, Jonathon R Campbell, Graeme Meintjes, et al.
Plos One|July 23, 2014
A subset of circulating blood mycobacteria-specific CD4 T cells can predict the time to Mycobacterium tuberculosis sputum culture conversionCatherine Riou, Clive M Gray, Masixole Lugongolo, et al.
The Lancet. Global Health|August 12, 2022
Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort studyMurray Dryden, Caroline Mudara, Caroline Vika, et al.
The Lancet. Infectious Diseases|October 10, 2021
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy studyAdam Penn-Nicholson, Sophia B Georghiou, Nelly Ciobanu, et al.
Southern African Journal of HIV Medicine|March 24, 2018
Adult antiretroviral therapy guidelines 2017Graeme Meintjes, Michelle A Moorhouse, Sergio Carmona, et al.
Pageof 7